Tuxobertinib

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameTuxobertinib
Drug Alias NameBDTX-189
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsEGFR exon 20 insertion mutations inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2EGFR exon 20 insertion mutations +[4] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkFrance +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBlack Diamond Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBlack Diamond Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A